| |
| |
|
| Insider
Information: |
Kakkis Emil D |
| Relationship: |
|
| City: |
Novato |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
603,534 |
|
|
Indirect Shares
|
2,268,639 |
|
|
| Direct
Value |
$26,857,607 |
|
|
|
Indirect Value
|
$94,141,463 |
|
|
| Total
Shares |
2,872,173 |
|
|
| Total
Value |
$120,999,070 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Biomarin Pharmaceutical Inc |
BMRN |
Chief Medical Officer |
2009-03-02 |
39,621 |
2009-03-02 |
4,654 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
|
2024-03-01 |
563,913 |
2024-03-01 |
2,263,985 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
106 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-04-01 |
4 |
OE |
$4.00 |
$72,000 |
D/D |
18,000 |
104,164 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-11-03 |
4 |
OE |
$18.11 |
$307,938 |
D/D |
17,000 |
114,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-09-02 |
4 |
AS |
$30.19 |
$543,384 |
D/D |
(18,000) |
115,304 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-10-01 |
4 |
AS |
$26.27 |
$472,878 |
D/D |
(18,000) |
115,304 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-10-31 |
4 |
AB |
$13.35 |
$4,233 |
D/D |
317 |
115,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-08-01 |
4 |
AS |
$32.34 |
$584,578 |
D/D |
(18,000) |
127,304 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-11-03 |
4 |
OE |
$6.13 |
$98,080 |
D/D |
16,000 |
131,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-09-02 |
4 |
OE |
$6.13 |
$36,780 |
D/D |
6,000 |
133,304 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-10-01 |
4 |
OE |
$6.13 |
$110,340 |
D/D |
18,000 |
133,304 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-07-07 |
4 |
AS |
$27.90 |
$505,076 |
D/D |
(18,000) |
145,304 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-06-02 |
4 |
AS |
$37.57 |
$677,367 |
D/D |
(18,000) |
160,804 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-04-29 |
4 |
OE |
$4.00 |
$300,000 |
D/D |
75,000 |
161,164 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-04-30 |
4 |
AB |
$10.37 |
$17,007 |
D/D |
1,640 |
162,804 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-05-01 |
4 |
AS |
$37.31 |
$674,857 |
D/D |
(18,000) |
162,804 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-07-07 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
163,304 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-06-02 |
4 |
OE |
$4.00 |
$64,000 |
D/D |
16,000 |
178,804 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-05-01 |
4 |
OE |
$4.00 |
$72,000 |
D/D |
18,000 |
180,804 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2016-12-22 |
5 |
GD |
$0.00 |
$0 |
D/D |
27,500 |
419,647 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2017-06-01 |
4 |
D |
$56.61 |
$56,950 |
D/D |
(1,006) |
430,569 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2017-05-21 |
4 |
D |
$57.47 |
$61,608 |
D/D |
(1,072) |
431,575 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
432,647 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2016-11-15 |
4 |
AS |
$79.39 |
$1,625,753 |
D/D |
(20,000) |
447,147 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2018-03-01 |
4 |
D |
$48.43 |
$53,951 |
D/D |
(1,114) |
448,955 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
19,500 |
450,069 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2018-06-01 |
4 |
D |
$73.73 |
$68,274 |
D/D |
(926) |
450,472 |
0 |
- |
|
106 Records found
|
|
Page 2 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
